On January 27, Bio-Thera Solutions Ltd(688177) released the performance forecast for 2021. It is expected that the operating revenue in 2021 will increase by 600 million yuan to 700 million yuan, a year-on-year increase of 324.34% to 378.40%. The net profit attributable to the owners of the parent company is expected to be 65 million yuan to 95 million yuan, turning losses into profits compared with the same period of last year. Meanwhile, the company expects to realize the net profit attributable to the owner of the parent company after deducting non recurring profits and losses of 27 million yuan to 40 million yuan. As a biological similar drug enterprise listed on the science and innovation board, Bio-Thera Solutions Ltd(688177) turned losses into profits the year after listing, showing excellent competitive strength.
Bio-Thera Solutions Ltd(688177) said that last year, the company actively expanded more global market share and conducted business cooperation with many enterprises at home and abroad. The licensing and commercialization agreement of tozumab injection was signed with Biogen International GmbH, and the phased milestone conditions agreed in the agreement were completed; At the same time, the company’s drug pubeshi (bevacizumab injection) obtained the drug registration certificate approved by the State Drug Administration, reached the phased milestone conditions in the licensing and commercialization agreement signed with Baiji, and the licensing income increased significantly.
In addition, the company has actively expanded the market, gradually expanded the business scale, and gradually increased the sales volume of gelolib (adalimumab injection). It is expected that the sales revenue will increase by 110 million yuan to 130 million yuan compared with the same period of last year, with a year-on-year increase of 60.15% to 71.09%.
